Skip to main content
1/1 journal selected

MAbs

Taylor & Francis (United Kingdom)

MAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are

MAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider MAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. Relevant topics include (but are not be limited to): Antibody engineering and selection Targets relevant to cancer, immune-mediated disorders, and other diseases Non-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animals Manufacturing Clinical studies Regulatory review of antibody therapeutics Post-approval topics, e.g., pricing, reimbursement and markets Patents Emerging markets for antibody therapeutics, including China and India

Animal health: multidiscip.
World health, public health
Human health
Open access
Self-archiving
Publication languages
  • English
Journal reputation
Other titles
Monoclonal antibodies
Abbreviated title (ISO)
MAbs
ISSN L
1942-0862
Frequency
6 issues/year (Bi-monthly)
Article types
Research articles
Reviews
Short articles
Commentaries
Conference reports
Opinions
Publishing costs
Yes
Total publishing costs
3840 € (updated 16/11/2023)
Research data access policy
Deposit recommended
Last updated : 16/11/2023

Ask a question, make a suggestion,
suggest a correction :

ou-publier@cirad.fr